A Sage event has heard South Africa's finance leaders say decision speed, not reporting, now defines the CFO role.
Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30% ...
Sage is over the hump in its transition to a primary cloud-focused software company. which means operating margins should rise going forward as the benefits of scale kick in.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results